American Journal of Clinical Dermatology

Papers
(The TQCC of American Journal of Clinical Dermatology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Rosacea: New Concepts in Classification and Treatment114
Sunscreens and Photoaging: A Review of Current Literature114
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review113
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments106
Psychosocial Effects of Vitiligo: A Systematic Literature Review103
Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments87
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program79
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study78
Erythema Nodosum: A Practical Approach and Diagnostic Algorithm78
Ceramides in Skin Health and Disease: An Update72
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis71
Clinical Course and Characteristics of Generalized Pustular Psoriasis66
Pathophysiology of Generalized Pustular Psoriasis66
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review65
Dermatitis Herpetiformis: An Update on Diagnosis and Management62
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)54
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis54
Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options51
The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses51
New Practical Aspects of Sweet Syndrome50
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study48
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies46
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review40
Deucravacitinib for the Treatment of Psoriatic Disease40
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)40
50 Years of Topical Retinoids for Acne: Evolution of Treatment39
Teledermatology During COVID-19: An Updated Review38
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma36
Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey35
Clinical Disease Measures in Generalized Pustular Psoriasis35
The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis35
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial35
Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice35
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials33
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study33
The Importance of Incorporating Human Factors in the Design and Implementation of Artificial Intelligence for Skin Cancer Diagnosis in the Real World33
Investigational Treatments for Epidermolysis Bullosa33
The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation31
Diagnosis of Generalized Pustular Psoriasis31
Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review30
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outco30
Hypertrophic Scars and Keloids: Advances in Treatment and Review of Established Therapies28
Behçet Disease: An Update for Dermatologists27
Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions27
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System27
New Topical Therapies for Psoriasis26
The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma25
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis25
HLA-Cw1 and Psoriasis25
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis25
JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety25
Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment24
Oral Lichen Planus: An Update on Diagnosis and Management24
Syphilis in Dermatology: Recognition and Management24
What’s New in Topicals for Atopic Dermatitis?23
Impact of Facial Atrophic Acne Scars on Quality of Life: A Multi-country Population-Based Survey23
A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions23
DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 202022
Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics21
Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study20
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination 20
Cutaneous Manifestations of SARS-CoV-2 Infection20
Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma19
Photoprotection for Skin of Color19
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors19
The Use of Lasers and Light Devices in Acne Management: An Update19
Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial19
A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris18
The Impact of Hyperhidrosis on Quality of Life: A Review of the Literature18
Effect of Vitamin D Serum Levels and Supplementation on Atopic Dermatitis: A Systematic Review and Meta-analysis18
Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management18
Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma18
Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists17
Generalized Pustular Psoriasis in Pregnancy: Current and Future Treatments17
Cholinergic Urticaria: Subtype Classification and Clinical Approach17
Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 202017
Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis17
Leukonychia: What Can White Nails Tell Us?17
Pediatric Mastocytosis: Recognition and Management17
Climate Change, Skin Health, and Dermatologic Disease: A Guide for the Dermatologist17
Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians17
Stasis Dermatitis: An Overview of Its Clinical Presentation, Pathogenesis, and Management16
Pruritus in Pregnancy16
Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions16
Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges16
Cellulitis: A Review of Current Practice Guidelines and Differentiation from Pseudocellulitis16
Tralokinumab for the Treatment of Atopic Dermatitis16
0.21975803375244